Literature DB >> 21994119

Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.

Conny Berlin1, Carles Blanch, David J Lewis, Dionigi D Maladorno, Christiane Michel, Michael Petrin, Severine Sarp, Philippe Close.   

Abstract

PURPOSE: The detection of safety signals with medicines is an essential activity to protect public health. Despite widespread acceptance, it is unclear whether recently applied statistical algorithms provide enhanced performance characteristics when compared with traditional systems. Novartis has adopted a novel system for automated signal detection on the basis of disproportionality methods within a safety data mining application (Empirica™ Signal System [ESS]). ESS uses two algorithms for routine analyses: empirical Bayes Multi-item Gamma Poisson Shrinker and logistic regression (LR).
METHODS: A model was developed comprising 14 medicines, categorized as "new" or "established." A standard was prepared on the basis of safety findings selected from traditional sources. ESS results were compared with the standard to calculate the positive predictive value (PPV), specificity, and sensitivity. PPVs of the lower one-sided 5% and 0.05% confidence limits of the Bayes geometric mean (EB05) and of the LR odds ratio (LR0005) almost coincided for all the drug-event combinations studied.
RESULTS: There was no obvious difference comparing the PPV of the leading Medical Dictionary for Regulatory Activities (MedDRA) terms to the PPV for all terms. The PPV of narrow MedDRA query searches was higher than that for broad searches. The widely used threshold value of EB05 = 2.0 or LR0005 = 2.0 together with more than three spontaneous reports of the drug-event combination produced balanced results for PPV, sensitivity, and specificity.
CONCLUSIONS: Consequently, performance characteristics were best for leading terms with narrow MedDRA query searches irrespective of applying Multi-item Gamma Poisson Shrinker or LR at a threshold value of 2.0. This research formed the basis for the configuration of ESS for signal detection at Novartis.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21994119     DOI: 10.1002/pds.2247

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1.  Choosing thresholds for statistical signal detection with the proportional reporting ratio.

Authors:  Jim Slattery; Yolanda Alvarez; Ana Hidalgo
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

2.  Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Authors:  Sheriza N Baksh; Mara McAdams-DeMarco; Jodi B Segal; G Caleb Alexander
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-04-14       Impact factor: 2.890

3.  Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.

Authors:  Zahra Anita Trippe; Bruno Brendani; Christoph Meier; David Lewis
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

4.  Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.

Authors:  R Harpaz; W DuMouchel; P LePendu; A Bauer-Mehren; P Ryan; N H Shah
Journal:  Clin Pharmacol Ther       Date:  2013-02-11       Impact factor: 6.875

5.  Toward enhanced pharmacovigilance using patient-generated data on the internet.

Authors:  R W White; R Harpaz; N H Shah; W DuMouchel; E Horvitz
Journal:  Clin Pharmacol Ther       Date:  2014-04-08       Impact factor: 6.875

6.  Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.

Authors:  Ola Caster; Kristina Juhlin; Sarah Watson; G Niklas Norén
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

7.  Web-Based Signal Detection Using Medical Forums Data in France: Comparative Analysis.

Authors:  Marie-Laure Kürzinger; Stéphane Schück; Nathalie Texier; Redhouane Abdellaoui; Carole Faviez; Julie Pouget; Ling Zhang; Stéphanie Tcherny-Lessenot; Stephen Lin; Juhaeri Juhaeri
Journal:  J Med Internet Res       Date:  2018-11-20       Impact factor: 5.428

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.